ASLN ASLAN Pharmaceuticals Limited

3.22
+0.19  (+6%)
Previous Close 3.03
Open 3.01
52 Week Low 1.42
52 Week High 6.75
Market Cap $224,167,423
Shares 69,617,212
Float 69,617,212
Enterprise Value $132,379,405
Volume 689,006
Av. Daily Volume 1,077,564
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ASLAN004
Atopic dermatitis
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
ASLAN003
Inflammatory bowel disease
Phase 2
Phase 2
Phase 2 trial to commence early 2022.
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2/3
Phase 2/3
Phase 3 trial did not meet primary endpoint - November 11, 2019.
Varlitinib
Gastric cancer
Phase 2/3
Phase 2/3
Phase 2 trial did not meet primary endpoint - January 13, 2019.

Latest News

  1. PRESS RELEASE

    16 September 2021

    Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders' meeting held on September 16, 2021. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership.

    "Robert's depth of experience leading and advising U.S.-listed companies on corporate finance, investor relations and related activities will be valuable as we continue to develop our board and evaluate a future U.S. listing…

    PRESS RELEASE

    16 September 2021

    Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders' meeting held on September 16, 2021. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership.

    "Robert's depth of experience leading and advising U.S.-listed companies on corporate finance, investor relations and related activities will be valuable as we continue to develop our board and evaluate a future U.S. listing," said J. Donald deBethizy, Chairman of the Saniona Board of Directors. 

    "I see in Saniona a company with a considerable amount of untapped potential. There is incredible depth in the pipeline and the talent, and I look forward to supporting and advising the team on how to ensure Saniona's potential is appreciated and valued," said Hoffman.

    Hoffman currently sits on three publicly-traded company boards with market capitalizations ranging from $30 million to $300 million (NASDAQ:ASLN, NASDAQ:KTRA, TSX:ATE), serving as chairman on one of the boards and as financial expert on the other boards. Hoffman also serves as a board member of the Association of Bioscience Financial Officers and FibroBiologics, Inc., a private biotechnology company. In his most recent operating role, Hoffman was Chief Financial Officer (CFO) of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed, commercial-stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. Hoffman's career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he was a member of the founding management team and rose to become CFO, holding that position for ten years. While at Arena, he was involved in its Initial Public Offering (IPO) and financings, raising more than $1.5 billion. Hoffman was the financial lead in two Arena acquisitions, including a Swiss manufacturing facility, and he became managing director of the facility upon the closing of the transaction. Hoffman also was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020), advising the United States accounting rulemaking organizations on emerging issues and new financial guidance. As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Hoffman has served on its board of directors for 20 years. Hoffman received his BBA in accounting from St. Bonaventure University and is a licensed CPA (Inactive) in the State of California.

    Hoffman is considered independent in relation to the company, its senior management and major shareholders. Hoffman does not own shares in Saniona.

    For more information, please contact

    Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

    The information was submitted for publication, through the agency of the contact person set out above, at 17.50 CEST on 16 September 2021.

    About Saniona

    Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company's lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 ion channel modulators, of which more than 20,000 are Saniona's proprietary compounds. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company's shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

     

    Attachment



    Primary Logo

    View Full Article Hide Full Article
  2. MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021.

    An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN's website at www.ir.aslanpharma.com and at the following link: https://journey.ct.events/view/1b10cdbc-a1e0-4f84-b475-753e1832a13a

    Media

    MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021.

    An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN's website at www.ir.aslanpharma.com and at the following link: https://journey.ct.events/view/1b10cdbc-a1e0-4f84-b475-753e1832a13a

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6206 7350

    Email: ASLAN@spurwingcomms.com

    Ashley R. Robinson

    LifeSci Advisors, LLC

    Tel: +1 (617) 430-7577

    Email: arr@lifesciadvisors.com

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.



    Primary Logo

    View Full Article Hide Full Article
    • Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis
    • Topline, unblinded data from approximately 27 additional patients expected at the end of the third quarter of 2021
    • On track to initiate Phase 2b clinical trial for ASLAN004 in 4Q 2021

    SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2021, and provided an update on recent corporate activities.

    "We have continued to make…

    • Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis
    • Topline, unblinded data from approximately 27 additional patients expected at the end of the third quarter of 2021
    • On track to initiate Phase 2b clinical trial for ASLAN004 in 4Q 2021

    SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2021, and provided an update on recent corporate activities.

    "We have continued to make significant progress in 2021, completing the enrolment of 27 additional patients into the expansion cohort of our MAD study of ASLAN004 and establishing a strong financial position to advance the clinical development of both ASLAN004 and ASLAN003, said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. "Earlier this year, we announced positive interim data from three dose cohorts, supporting the potential of ASLAN004 as a novel, first-in-class antibody targeting the IL-13 receptor with differentiated efficacy and safety profile. At the end of the third quarter, we expect to announce new, unblinded data from the MAD study from approximately 27 additional patients."

    Second quarter 2021 and recent business highlights

    Clinical development

    ASLAN004

    • In May, new data from the Single Ascending Dose study were presented in a late-breaking poster presentation at the 2021 Society for Investigative Dermatology virtual meeting. The data demonstrated ASLAN004's favourable tolerability profile as an IL-13Rα1 inhibitor and its potential as a differentiated treatment method for atopic dermatitis. The data will also be published in the fall edition of the Journal of Investigative Dermatology.
    • In June, recruitment of 27 patients into the expansion cohort of the double-blind placebo-controlled MAD study was completed. Topline data is expected to be announced at the end of the third quarter 2021.

    ASLAN003

    • ASLAN is preparing to advance ASLAN003 as a candidate for the potential treatment of autoimmune gastrointestinal and skin diseases. The initiation of a Phase 2 clinical trial for ASLAN003 in inflammatory bowel disease is planned for early 2022.

    Corporate updates

    • In July, ASLAN secured a loan facility with K2 HealthVentures of up to US$45.0 million of secured debt financing. The facility consists of a US$20.0 million initial term loan funded at closing, with the remaining US$25.0 million subject to certain terms and conditions. The proceeds will be used to advance the clinical development of ASLAN003 as well as for general corporate purposes.

    Anticipated upcoming milestones

    • Completion of MAD clinical study of ASLAN004 in moderate-to-severe atopic dermatitis (AD) patients with topline results expected at the end of the third quarter of 2021.
    • Initiation of Phase 2b study of ASLAN004 for AD expected in the last quarter of 2021.
    • Initiation of Phase 2 study of ASLAN003 in inflammatory bowel disease in early 2022.

    Second quarter 2021 financial highlights

    • Cash used in operations for the second quarter of 2021 was US$6.9 million compared to US$3.0 million in the same period in 2020.
    • Research and development expenses were US$4.0 million in the second quarter of 2021 compared to US$1.9 million in the second quarter of 2020. The increase was driven primarily by preparations for the ASLAN004 Phase 2b clinical trials.
    • General and administrative expenses were US$3.8 million in the second quarter of 2021 compared to US$1.8 million in the second quarter of 2020. The increase was driven by costs related to the financing activities completed in the first half of the year and employee costs.
    • Net loss for the second quarter of 2021 was US$5.5 million compared to a net loss of US$4.0 million for the second quarter of 2020. The company booked a gain of US$2.3 million on dilution of its subsidiary and recognition of its associate in the second quarter of 2021.
    • Cash and cash equivalents totalled US$94.1 million as of June 30, 2021, compared to US$14.3 million as of December 31, 2020, and included the combined gross proceeds raised of approximately US$101.6 million from the financing activities conducted in the second quarter of 2021. With the proceeds from these financing activities and the loan facility secured from K2 HealthVentures, management believes that ASLAN's cash and cash equivalents will be sufficient to fund operations through late 2023.
    • The weighted average number of ADSs outstanding in the computation of basic loss per share for the second quarter of 2021 was 69.6 million (representing 348 million ordinary shares) compared to 38 million (representing 190 million ordinary shares) for the second quarter of 2020. Following the financing activities in the second quarter of 2021, the number of ADSs outstanding on 30 June 2021 was 69.6 million (representing 348 million ordinary shares). One ADS is the equivalent of five ordinary shares.



    ASLAN Pharmaceuticals Limited

    CONSOLIDATED BALANCE SHEETS

    (In US Dollars)

      December 31, 2020

    (audited)
     June 30, 2021

    (unaudited)
    ASSETS    
         
    CURRENT ASSETS    
    Cash and cash equivalents $14,324,371  $94,120,158 
    Other receivables  528,841   - 
    Prepayments  511,208   615,212 
    Financial assets at fair value through profit or loss  137,926   - 
    Total current assets  15,502,346   94,735,370 
         
    NON-CURRENT ASSETS    
    Investment in associates company  -   818,560 
    Property, plant and equipment  13,387   8,678 
    Right-of-use assets  462,550   330,148 
    Intangible assets  160   12,016 
    Refundable deposits  103,307   120,050 
    Total non-current assets  579,404   1,289,452 
         
    TOTAL ASSETS $16,081,750  $96,024,822 
         
    LIABILITIES AND EQUITY    
         
    CURRENT LIABILITIES    
    Trade payables $2,319,558  $2,046,787 
    Other payables  4,280,409   2,791,630 
    Current portion of long-term borrowing  2,900,971   - 
    Current portion of long-term borrowing from related parties  617,912   - 
    Lease liabilities - current  271,624   281,309 
    Financial liabilities at fair value through profit or loss  267,000   - 
    Total current liabilities  10,657,474   5,119,726 
         
    NON-CURRENT LIABILITIES    
    Long-term borrowings  15,183,421   15,214,780 
    Lease liabilities - non-current  281,149   63,322 
    Other non-current liabilities  111,990   272,242 
    Total non-current liabilities  15,576,560   15,550,344 
         
    Total liabilities  26,234,034   20,670,070 
         
    EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY    
    Ordinary shares  61,826,237   63,013,589 
    Capital surplus  123,582,460   220,352,368 
    Accumulated deficits  (195,682,714)   (207,832,257) 
    Other reserves  (178,948)   (178,948) 
         
    Total equity attributable to stockholders of the Company  (10,452,965)   75,354,752 
         
    NON-CONTROLLING INTERESTS  300,681   - 
         
    Total equity  (10,152,284)   75,354,752 
         
    TOTAL LIABILITIES AND EQUITY $16,081,750  $96,024,822  
         

    ASLAN Pharmaceuticals Limited

    CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

    (In US Dollars, other than shares or share data)

     For the Three Months Ended June 30 For the Six Months Ended June 30
      2020  2021  2020  2021 
    NET REVENUE$- $- $- $- 
                 
    COST OF REVENUE -  -  -  - 
                 
    GROSS PROFIT -  -  -  - 
                 
    OPERATING EXPENSES    
    General and administrative expenses (1,790,880)  (3,788,772)  (2,788,423)  (6,893,836) 
    Research and development expenses (1,892,559)  (4,044,521)  (4,247,175)  (7,795,493) 
    Total operating expenses (3,683,439)  (7,833,293)  (7,035,598)  (14,689,329) 
                 
    LOSS FROM OPERATIONS (3,683,439)  (7,833,293)  (7,035,598)  (14,689,329) 
                 
    NON-OPERATING INCOME AND EXPENSES    
    Other income -  340,076  -  340,076 
    Interest income 114  20  216  157 
    Gain on dilution of subsidiary and recognition of associate -  2,307,735  -  2,307,735 
    Other gains and losses (65,816)  22,451  391,435  319,636 
    Finance costs (338,612)  (203,428)  (677,637)  (614,902) 
    Total non-operating income and expenses (404,314)  2,466,854  (285,986)  2,352,702 
                 
    Share in losses of associated company, accounted for using equity method -  (81,880)  -  (81,880) 
    LOSS BEFORE INCOME TAX (4,087,753)  (5,448,319)  (7,321,584)  (12,418,507) 
                 
    INCOME TAX EXPENSE -  -  -  - 
                 
    NET LOSS FOR THE PERIOD (4,087,753)  (5,448,319)  (7,321,584)  (12,418,507) 
                 
    OTHER COMPREHENSIVE LOSS    
    Items that will not be reclassified subsequently to profit or loss:    
    Unrealized loss on investments in equity instruments at fair value through other comprehensive income 

    (39,324)
      

    -
      

    (74,331)
      

    -
     
    TOTAL COMPREHENSIVE LOSS FOR THE PERIOD$(4,127,077) $(5,448,319) $

    (7,395,915) $(12,418,507) 
                 
    NET LOSS ATTRIBUTABLE TO:    
    Stockholders of the Company$(3,959,184) $(5,429,026) $(7,005,889) $(12,149,543) 
    Non-controlling interests (128,569)  (19,293)  (315,695)  (268,964) 
     $(4,087,753) $(5,448,319) $(7,321,584) $(12,418,507) 
                 
    TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO:    
    Stockholders of the Company$(3,998,508) $(5,429,026) $(7,080,220) $(12,149,543) 
    Non-controlling interests (128,569)  (19,293)  (315,695)  (268,964) 
     $(4,127,077) $(5,448,319) $(7,395,915) $(12,418,507) 
    LOSS PER ORDINARY SHARE    
    Basic and diluted$(0.02) $(0.02) $(0.04) $(0.04) 
    LOSS PER EQUIVALENT ADS    
    Basic and diluted$(0.10) $(0.08) $(0.20) $(0.20) 
    Weighted-average number of ordinary shares in the computation of basic loss per ordinary share 

    189,954,970
      

    347,799,933
      

    189,954,970
      

    302,985,377
     
    Weighted-average number of ADS in the computation of basic loss per ADS 37,990,994  69,559,987  37,990,994  60,597,075 

    Each ADS represents five ordinary shares.



    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6206 7350

    Email: ASLAN@spurwingcomms.com

    Ashley R. Robinson

    LifeSci Advisors, LLC

    Tel: +1 (617) 430-7577

    Email: arr@lifesciadvisors.com

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in the Bay Area and in Singapore. For additional information, please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy and clinical development plans; the Company's plans to develop and commercialise ASLAN003 and ASLAN004; the safety and efficacy of ASLAN003 and ASLAN004; the Company's plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for ASLAN003 and ASLAN004; the potential for ASLAN003 and ASLAN004 as treatments for autoimmune disease and atopic dermatitis, respectively; the total amount of the debt financing to be provided by the loan facility with K2 HealthVentures; and the Company's belief that its cash and cash equivalents will be sufficient to fund operations into late 2023. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company's business and the global economy; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 23, 2021. All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.



    Primary Logo

    View Full Article Hide Full Article
  3. SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing. The facility consists of a $20 million initial term loan funded at closing, with the remaining $25 million subject to certain terms and conditions.

    The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal…

    SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing. The facility consists of a $20 million initial term loan funded at closing, with the remaining $25 million subject to certain terms and conditions.

    The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal and skin diseases, as well as for general corporate purposes. ASLAN expects to initiate a phase 2 clinical trial for ASLAN003 in inflammatory bowel disease in early 2022.

    Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "These resources provide additional working capital, strengthen our balance sheet, and enhance our financial flexibility by extending our expected cash runway through late 2023, as we look forward to expanding our clinical activities for ASLAN003. We are excited to be partnering with the K2HV team with its significant experience supporting innovative life science companies."  

    "We're delighted to provide support to ASLAN as it approaches key value-creating milestones in the development of ASLAN003 and ASLAN004 in the next twelve months," added Anup Arora, Founding Managing Director and Chief Investment Officer at K2HV. "ASLAN's commitment to developing novel treatments that have the potential to transform the lives of patients is wholly aligned with our investment strategy. We look forward to working with the ASLAN team to realise its vision."

    In addition, under the terms of the financing, ASLAN intends to pay off its outstanding loans with CSL Finance Pty Ltd in the amount of $4.2 million.

    Armentum Partners served as financial advisor to ASLAN in connection with the financing. Further information with respect to the loan facility will be set forth in a Form 6-K that ASLAN plans to file with the Securities and Exchange Commission upon closing.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6206 7350

    Email: ASLAN@spurwingcomms.com

    Ashley R. Robinson

    LifeSci Advisors, LLC

    Tel: +1 (617) 430-7577

    Email: arr@lifesciadvisors.com   

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in the Bay Area and in Singapore. For additional information, please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy and clinical development plans; the Company's plans to develop and commercialise ASLAN003 and ASLAN004; the safety and efficacy of ASLAN003 and ASLAN004; the Company's plans and expected timing with respect to clinical trials and clinical trial results for ASLAN003 and ASLAN004; the potential for ASLAN003 and ASLAN004 as treatments for autoimmune disease and atopic dermatitis respectively; the total amount of the debt financing to be funded; and the Company's belief that its cash and cash equivalents will be sufficient to fund operations into late 2023. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company's business and the global economy; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 23, 2021. All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

    About K2 HealthVentures

    K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. The investment team comprises collaborative, experienced professionals with diverse backgrounds in finance and operations, as well as deep domain knowledge across various healthcare sectors. A uniquely flexible, permanent capital structure enables the firm to provide creative, adaptive financing solutions and meet the evolving capital needs of its portfolio companies as they grow. K2HV is driven by dual goals of Profit and Purpose – aiming to fuel the growth of innovative companies that will ultimately improve the lives of patients and giving a percentage of investment profits back to underserved areas in healthcare. www.k2hv.com



    Primary Logo

    View Full Article Hide Full Article
  4. SINGAPORE, May 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.

    A live webcast of the chat will be available using this link: https://wsw.com/webcast/jeff174/asln/1851714 and in the Investor Relations section of ASLAN's website at www.aslanpharma.com, with a replay available shortly after the event.

    Media and IR contacts

    Emma Thompson
    Spurwing Communications

    SINGAPORE, May 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.

    A live webcast of the chat will be available using this link: https://wsw.com/webcast/jeff174/asln/1851714 and in the Investor Relations section of ASLAN's website at www.aslanpharma.com, with a replay available shortly after the event.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email: ASLAN@spurwingcomms.com

    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email: robert.uhl@westwicke.com
      

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy and clinical development plans; the Company's plans to develop and commercialise ASLAN004; the safety and efficacy of ASLAN004; the Company's plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004; the potential for ASLAN004 as a differentiated treatment for atopic dermatitis; and the Company's belief that its cash and cash equivalents will be sufficient to fund operations into 2023. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company's business and the global economy; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 23, 2021.

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.



    Primary Logo

    View Full Article Hide Full Article
View All ASLAN Pharmaceuticals Limited News